BioSpace News Archive

IN8bio, Inc. announced an abstract detailing new, positive data from the Phase 1 investigator-sponsored trial of INB-100 in patients with hematologic malignancies has been selected for poster presentation at the 65th American Society of Hematology Annual Meeting and Exposition taking place December 9-12, 2023.

Precision Biologics will deliver a poster presentation on preliminary results of the ongoing phase 2 trial, combining NEO-201 with pembrolizumab for the treatment of patients resistant to prior checkpoint inhibitor therapy at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting at the San Diego Convention Center in San Diego, CA on November 3rd, 2023.

Rallybio Announces Acceptance of FNAIT Natural History Study Abstract for Presentation at the 65th American Society of Hematology Annual Meeting.

Legend Biotech Corporation today announced that two oral presentations and five poster presentations featuring new and updated data from the CARTITUDE clinical development program evaluating ciltacabtagene autoleucel (cilta-cel) will be presented at the 65th American Society of Hematology Annual Meeting and Exposition taking place in San Diego from December 9-12.

Co-Diagnostics, Inc. (Nasdaq: CODX) (the “Company” or “Co-Dx”), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced a grant awarded by the Bill & Melinda Gates Foundation to support the tuberculosis (TB) test in development, designed to be run on the upcoming Co-Dx™ PCR platform*.

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced the upcoming presentation of four posters highlighting data from their commercial and clinical-stage hematology-oncology portfolio at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition being held December 9-12, 2023, in San Diego, California and virtually.

bluebird bio, Inc. announced that new long-term efficacy, safety and health-related quality of life follow-up data from its lentiviral vector gene therapy programs in patients with sickle cell disease who have a history of vaso-occlusive events and patients with beta-thalassemia who require regular red blood cell transfusions will be presented at the 65th American Society of Hematology Annual Meeting and Exposition.

Medeor Therapeutics announced positive interim data from its multicenter, international Phase III clinical trial.

The Multiple Myeloma Research Foundation announced the recipients of three $7 million MMRF Myeloma Accelerator Challenge Program Grants totaling $21 million.

Catalyst Pharmaceuticals, Inc. announced that the Company has received notification by the United States Patent and Trademark Office that two additional patents covering FIRDAPSE® Tablets 10 mg, were allowed and will be granted within the next two months.